Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Maintains Outperform on ZoomInfo Technologies, Raises Price Target to $70

RBC Capital analyst Rishi Jaluria maintains ZoomInfo Technologies (NASDAQ:ZI) with a Outperform and raises the price target from $60 to $70.

byBenzinga Newsdesk

August 3, 2021

1 minute read

RBC Capital analyst Rishi Jaluria maintains ZoomInfo Technologies (NASDAQ:ZI) with a Outperform and raises the price target from $60 to $70.

Oppenheimer Initiates Coverage On Harmony Biosciences with Outperform Rating, Announces Price Target of $55

By Benzinga Newsdesk

December 1, 5:59 AM

Oppenheimer analyst Francois Brisebois initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $55.

HRMY

Allied Corp Ships Second Commercial Cannabis Flower Export From Colombia To International Market

By Vuk Zdinjak

July 14, 11:32 AM

Allied Corp. (OTCQB: ALID) has completed its second shipment of commercial dried cannabis from Colombia to an international market.

ALID

Deutsche Bank Upgrades Gap to Buy, Raises Price Target to $42

By Benzinga Newsdesk

July 26, 8:14 AM

Deutsche Bank analyst Gabriella Carbone upgrades Gap (NYSE:GPS) from Hold to Buy and raises the price target from $38 to $42.

GPS

Analyst Ratings

Analyst Ratings for NGM Biopharmaceuticals

By Benzinga Insights

October 18, 12:39 PM

NGM Biopharmaceuticals (NASDAQ:NGM) has observed the following analyst ratings within the last quarter:

NGM

RBC Capital Maintains Outperform on ZoomInfo Technologies, Raises Price Target to $70

Related Posts

Oppenheimer Initiates Coverage On Harmony Biosciences with Outperform Rating, Announces Price Target of $55

Allied Corp Ships Second Commercial Cannabis Flower Export From Colombia To International Market

Deutsche Bank Upgrades Gap to Buy, Raises Price Target to $42

Analyst Ratings for NGM Biopharmaceuticals